Home > News > More on IBM's Supercomputer
June 21st, 2005
Abstract:
Jack Uldrich: Last Friday, I had an article on IBM's new supercomputer run in The Motley Fool. One reader questioned my choice of listing Affymetrix as a competitor. It was a fair question and I responded that because Affymetrix was involved in trying to establish genetic links to a variety of diseases for the purposes of drug discovery, I felt IBM's use of its new supercomputer to the same ends could adversely affect Affyxmetrix's business.
Source:
NanoNovus
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||